Seems like there's a bit of interest in the NGPDT...

Seems like there's a bit of interest in the NGPDT technology.

https://www.globenewswire.com/news-release/2019/01/29/1707012/0/en/Velt-International-Group-Inc-Acquires-Two-Cancer-Treatment-Related-Companies.html

Velt International Group Inc. Acquires Two Cancer Treatment Related Companies

Thousand Oaks, California, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Velt International Group Inc. (OTC Pink: VIGC) (the “Company” or “Velt”) today announced that on January 24, 2019 it has executed an agreement to acquire all of the issued and outstanding shares of THF International (Hong Kong) Ltd (“THF International”), a Hong Kong cancer treatment and medical device company, together with its two South Africa subsidiaries. On January 25, 2019, the Company executed another agreement to acquire all of the issued and outstanding shares of Natural Health Farm (Labuan) Inc. (“NHF”), a Malaysian offshore company that owns exclusive license of a cancer treatment technology for Sub-Sahara African region.Under the agreement with THF International, Velt has acquired 100% issued and outstanding shares of THF International and its wholly owned South African companies for the aggregated amount of USD 2 Million. Velt shall issue shares equivalent to the acquisition amount based on closing share price on January 24, 2019. Rural Asset Management Services, Inc. (“RAM”) owns 90% issued and outstanding shares of THF International and on December 14, 2018 RAM acquired 1,132,000 shares of Velt, which makes it a majority shareholder of the Company.Under the agreement with NHF, Velt has acquired 100% issued and outstanding shares of NHF for the aggregated amount of USD 10 Million. Velt shall issue shares equivalent to the acquisition amount based on closing share price on January 25, 2019. According to the agreement, the value of the exclusive license for the cancer treatment technology shall be evaluated by an independent third party appraiser, and if the license value of assessment is below USD 10 Million, then the assessment value shall be applied for exchanging the shares of the Company. If the assessment value of the license is more than USD 10 Million, the Company and NHF agree to use USD 10 Million as the acquisition price to exchange the shares of the Company.Ali Kasa, the CEO and President of the Company said, “The acquisition of THF International and its subsidiaries in South Africa is another major milestone for Velt within the healthcare sector. We believe this acquisition will create significant shareholder value and we are highly confident that this technology related to cancer treatment is going to significantly help humans battling deadly disease.” “The acquisition of NHF is also another exciting news for us as it completes all the ingredients required to venture into cancer treatment. The exclusive license of Next Generation Photo Dynamic Therapy (NGPDT) is currently undergoing medical human trials in Australia by Invion Ltd an Australian Publicly traded company on Australian Stock Exchange under the symbol IVX, exclusive licensee for Australia and New Zealand.”